## **Chen-Ching Yuan**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11859853/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular basis of force-pCa relation in <i>MYL2</i> cardiomyopathy mice: Role of the super-relaxed state of myosin. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	23
2	Cardiac myosin activation with 2-deoxy-ATP via increased electrostatic interactions with actin. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11502-11507.	7.1	30
3	Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM. Journal of Molecular Medicine, 2019, 97, 1033-1047.	3.9	15
4	Slowâ€ŧwitch skeletal muscle defects accompany cardiac dysfunction in transgenic mice with a mutation in the myosin regulatory light chain. FASEB Journal, 2019, 33, 3152-3166.	0.5	11
5	Sarcomeric perturbations of myosin motors lead to dilated cardiomyopathy in genetically modified <i>MYL2</i> mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2338-E2347.	7.1	28
6	Single cardiac ventricular myosins are autonomous motors. Open Biology, 2018, 8, 170240.	3.6	16
7	Cardiac contractility, motor function, and crossâ€bridge kinetics in N47K―RLC mutant mice. FEBS Journal, 2017, 284, 1897-1913.	4.7	5
8	Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice. Cardiovascular Research, 2017, 113, 1124-1136.	3.8	23
9	Proteomic analysis of physiological versus pathological cardiac remodeling in animal models expressing mutations in myosin essential light chains. Journal of Muscle Research and Cell Motility, 2015, 36, 447-461.	2.0	8
10	Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4138-46.	7.1	63
11	Novel familial dilated cardiomyopathy mutation in <i><scp>MYL</scp>2</i> affects the structure and function of myosin regulatory light chain. FEBS Journal, 2015, 282, 2379-2393.	4.7	42
12	Remodeling of the heart in hypertrophy in animal models with myosin essential light chain mutations. Frontiers in Physiology, 2014, 5, 353.	2.8	13
13	Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H575-H589.	3.2	31
14	Structural and functional aspects of the myosin essential light chain in cardiac muscle contraction. FASEB Journal, 2011, 25, 4394-4405.	0.5	44